Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Olaparib In Metastatic Breast Cancer
NCT03344965 · View on ClinicalTrials.gov ↗
Study Summary
This research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged. * This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib. * Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that make them sensitive to similar treatments. Information from those other research studies suggests that this drug may help to treat metastatic breast cancer. * This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been inherited from a parent, or may have developed only in the tumor. * This study will also evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the tumor, but not inherited.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (20)
New York
- Memorial Sloan Kettering Cancer Center Commack — Commack
- Memorial Sloan Kettering Cancer Center Westchester — East White Plains
- Memorial Sloan Kettering Cancer Center — New York
- Memorial Sloan Kettering Cancer Center Nassau — Uniondale
Massachusetts
- Beth Israel Deaconess Medical Center — Boston
- Brigham and Women's Hospital — Boston
- Dana-Farber Cancer Institute — Boston
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge — Basking Ridge
- Memorial Sloan Kettering Cancer Center Monmouth — Middletown
- Memorial Sloan Kettering Cancer Center Bergen — Montvale
Pennsylvania
- UPMC Hillman Cancer Center - Erie — Erie
- University of Pennsylvania — Philadelphia
- University of Pittsburgh — Pittsburgh
Alabama
- University of Alabama at Birmingham — Birmingham
California
- University of California, San Francisco — San Francisco
Illinois
- University of Chicago — Chicago
Indiana
- Indiana University — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344965
The ClinicalTrials.gov registry entry for NCT03344965 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which Olaparib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03344965 reports 20 study locations spanning 11 distinct geographic areas — top geographies include New York, Massachusetts, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03344965 about?
NCT03344965 is a clinical study titled "Olaparib In Metastatic Breast Cancer". This research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA)...
What is the current status of trial NCT03344965?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-04-01. Estimated completion is 2026-06-30.
What conditions does trial NCT03344965 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Invasive Breast Cancer, ATM Gene Mutation, PALB2 Gene Mutation, BRIP1 Gene Mutation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03344965?
The interventions under investigation include: Olaparib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03344965?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03344965 being conducted?
This trial has 20 study locations across Alabama, California, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.